LOS ANGELES--(BUSINESS WIRE)--Sept. 20, 2006--A new molecule designed to battle advanced metastatic melanoma doubles the Progression-Free Survival rate of cancer patients compared with those receiving a conventional treatment, according to Steven O’Day, M.D., chief of research and director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles. Dr. O’Day, who served as principal investigator of a multicenter study to evaluate the new molecule, presented the full study results Saturday, September 16, at a joint melanoma conference taking place near Amsterdam.
